Tritylolmesartanethylester CAS:144690-33-5

Tritylolmesartanethylester inonyanya kukosha mukugadzirwa kwemishonga uye kuwanikwa kwemishonga, kunyanya mukugadzirwa kwemishonga inodzivirira angiotensin II ine mapuroteni akawedzerwa emishonga. Semushonga unozivikanwa we olmesartan medoxomil, mushonga uyu unoshanda senzira yakakosha yekugadzira uye kuongorora mishonga mitsva ine simba rakavandudzwa uye hunhu hwe pharmacokinetic. Mukutsvagisa kwemishonga, Tritylolmesartanethylester inodzidzwa nekuda kwekugona kwayo kugadzirisa renin-angiotensin system, iyo inoita basa rakakosha mukudzora BP, kuenzana kwemvura, uye mashandiro emwoyo. Nekuferefeta kushanda kwayo ne angiotensin II receptors, vaongorori vanovavarira kugadzira mishonga mitsva inogona kudzivirira zvinobudirira mhedzisiro yemuviri ye angiotensin II, zvichitungamira mukugadzirwa kwemishonga inotevera yekurwisa BP ine mhedzisiro iri nani yekurapa uye mhedzisiro yakaderera. Uyezve, kugadziriswa kwechimiro uye kuongororwa kwemishonga kwe Tritylolmesartanethylester uye ma analogues ayo kunobatsira mukunzwisisa hukama hwechimiro-basa (SAR) mukati mekirasi ye angiotensin receptor antagonist. Ruzivo urwu runotungamira dhizaini ine musoro yemishonga yakagadziriswa ine hukama hwakanaka hwemareceptor binding, selectivity, uye metabolic stability, zvichigadzira nzira yekufambira mberi mukurapa zvirwere zvemwoyo zvakaita seBP, heart failure, uye diabetic nephropathy. Uyezve, mashandisirwo anogona kuitwa neTritylolmesartanethylester anosvika kuzvidzidzo zve preclinical zvakanangana nekujekesa ma pharmacokinetic ayo uye pharmacodynamic profiles, chepfu profiles, uye therapeutic potential kuburikidza ne in vitro uye in vivo experiments. Kuferefeta uku kunopa data rakakosha rekuongorora kuchengetedzeka kwayo uye kushanda kwayo, zvichizotsigira kufambira mberi kwayo kuenda kumiedzo yekiriniki uye potential pharmaceutical development. Mukupfupisa, mashandisirwo eTritylolmesartanethylester anosanganisira basa rayo guru mukurapa chemistry uye pharmaceutical research sepuratifomu yekugadzira, kugadzira, uye kuongorora ma receptor antagonist matsva e angiotensin II, zvichibatsira mukufambira mberi kwe antihypertensive therapy uye cardiovascular pharmacology.